<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495313</url>
  </required_header>
  <id_info>
    <org_study_id>COL101-ROSE-401</org_study_id>
    <nct_id>NCT00495313</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens</brief_title>
  <official_title>Determine the Effects of COL-101 Administered Once Daily With Metronidazole Topical Gel, 1% Versus Doxycycline Hyclate 100 mg Administered Once Daily With Metronidazole Topical Gel, 1% in Patients With Moderate to Severe Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CollaGenex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CollaGenex Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole
      gel 1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole gel
      1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total lesion count from Baseline at the study endpoint</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Investigator's Global Assessment from Baseline at the study endpoint</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinician's Erythema Assessment score from Baseline at the study endpoint</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lesion count (papules + pustules + nodules) from Baseline at each visit</measure>
    <time_frame>4 weeks, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Cohort 1: doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vibramycin plus metronidazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oracea® delayed release plus metronidazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>COL-101, QD plus metronidazole</description>
    <arm_group_label>Cohort 1: doxycycline</arm_group_label>
    <other_name>Vibramycin, 100 mg, QD plus metornidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>40 mg with metronidazole QD</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Oracea® 40 mg plus metronidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  8-40 total lesions

          -  erythema

          -  telangiectasia

        Exclusion Criteria:

          -  non-pregnant, non-lactating

          -  achlorhydric

          -  gastric by-pass surgery

          -  allergy to study medications

          -  drug/alcohol abuse

          -  use of proton pump inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher V Powala, JD</last_name>
    <role>Study Chair</role>
    <affiliation>CollaGenex Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joel Schlessinger</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Del Rosso</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angela Moore</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Abramovits</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Douglas Forsha</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernard Goffe</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Werschler</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>December 11, 2008</last_update_submitted>
  <last_update_submitted_qc>December 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>C. Powala, VP, Drug Development &amp; Regulatory Affairs</name_title>
    <organization>CollaGenex Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

